Search results | bacterial

Reports

Bacterial Partnering Terms and Agreements

The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Both, Actavis and Sanofi competing for Omega Pharma

Several companies are rumored to be competing to acquire Omega Pharma, the fastest growing consumer healthcare company in the U.K. and Ireland.

Cubist Pharma, the next acquisition target for big pharmaceuticals

The timing may be right for a takeover of Cubist Pharmaceuticals.

Current Agreements Deal Analysis Update : July 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in June 2014.

Antibiotics

The term antibiotics was first used in 1942 by Selman Waksman and his collaborator

Novartis

Novartis is a top pharmaceutical company based in Basel, Switzerland

The Medicines Company: Competing to become the leader in acute and intensive care treatments

The Medicines Company is a global biopharmaceutical company currently ranked at no.21 in the global biotechnology top 50. The company develops medical solutions for acute and intensive care in hospitals and is aiming to become a leader in this area.

Daiichi Sankyo

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan

Cubist: Partnering activity 2009-2014

Cubist, a leading biopharmaceutical company focusses in the discovery, development and commercialization of novel acute care therapies.

Current Agreements Deal Analysis Update : March 2014

This month we provide you with an overview of deal analysis life science deal making activity, covering partnering, M&A and financing in February 2014

Current Agreements Deals Update : February 2014

This month we provide you with an overview of deal analysis life science deal making activity, covering partnering, M&A and financing in January 2014

Events

Sorry, your search returned no results.


Deals

Big pharma company Forest joins forces with Nabriva in anti-bacterial co-development pact

Forest Laboratories, a big pharma company is paying Nabriva Therapeutics $25 million in a co-development deal for Nabriva’s antibacterial agent, BC-3781, and the right to acquire Nabriva over the next 12 months

BioRelix Pharmaceuticals Enters Antibacterial Collaboration with Merck & Co

BioRelix will apply its proprietary riboswitch technology platform to identify compounds with activity against a number of bacterial targets. The parties will jointly undertake preclinical programs, and Merck will subsequently be responsible for clinical evaluation of any candidates chosen for further development.

PPD and Janssen Pharmaceutica collaborate to develop compounds for treatment of irritable bowel syndrome and bacterial infections

Under two agreements, PPD in-licensed the two assets and will advance the compounds through Phase II development.

Series A financing for $41 million for Symbiomix

Symbiomix Therapeutics announced multiple milestones, including the closing of the third and final tranche of a $41 million Series A financing and positive results from a multi-center, randomized Phase 2 trial testing a single oral dose of SYM-1219 for the treatment of bacterial vaginosis (BV).

Nabriva banks $120mn series B

Nabriva Therapeutics announced the successful completion of a $120 million Series B financing

Curevac bags $52 million from Bill and Melinda Gates Foundation

The Bill & Melinda Gates Foundation and CureVac announced that the foundation has made a commitment to invest $52 million (€46 million) in CureVac

GSK acquires GlycoVaxyn for $190 million

GSK has acquired GlycoVaxyn

Melinta bags $30 million in debt financing

Melinta Therapeutics has entered into a $30 million growth capital debt financing agreement with Hercules Technology Growth Capital

Emergent acquires Eisai’s EV-035 series technology

Evolva Holding announced that Emergent BioSolutions has acquired Evolva’s anti-bacterial programme, the EV-035 series

Actavis acquires Durata Therapeutics for $675 million

Actavis and Durata Therapeutics have inked a definitive  agreement to acquire Durata Therapeutics for $675 million.